略過巡覽連結
全部類別
照片
影音新聞
政府機關
國內公司行號
國外公司行號
非營利組織
中文稿
英文稿
有附件
無附件
受理採訪通知

會員登入
| 舒適閱覽 :

New patient survey reveals: For people with atrial fibrillation, reversal of their blood thinning treatment is highly important

•89% of surveyed patients with atrial fibrillation (AF) are aware of potential complications which may arise due to their blood thinning treatment in the event of an emergency
•The majority (83%) considered it important to know about a medication which could stop the blood thinning (anticoagulant) effects of their medication if needed
•For AF patients, doctors are the #1 source for information: 78% stated that they would prefer to receive information about reversibility of anticoagulant medication from their doctor

(中央社訊息服務20180629 09:41:24)INGELHEIM, Germany -- (BUSINESS WIRE) --
Results from a survey in five countries among 902 people living with atrial fibrillation (AF) reinforce the importance of patient-physician discussion around the reversal of blood thinning (anticoagulant) treatments in potential emergency situations.

AF is the most common cardiac rhythm disorder worldwide1 and increases the risk of stroke five-fold.2 Blood thinning treatments, known as anticoagulants, reduce the blood’s ability to form clots and reduce the risk of stroke. However, in emergency situations, such as when rapid initiation of surgery is required, or in the case of a life-threatening bleed, quick reversal of anticoagulation may be required.

AF patients in the survey were very aware of potential complications related to their treatment in the event of an emergency (89%).3 However, more than half (51%) could not recall having a discussion with their doctor about stopping their blood thinning medication in an emergency. Yet 78% would prefer such information about reversibility to come directly from their treating physician compared to other possible sources.

“First of all, it is important that AF patients understand the importance of anticoagulation and its role in preventing strokes. However, it is clear from these survey results that knowing more about how anticoagulant medication could be stopped in the event of an emergency is also very important to patients. This highlights the need for physicians to address this topic in ongoing discussions with their AF patients,” commented Professor Harald Darius, head of the department of cardiology, angiology, nephrology and intensive-care medicine at the Vivantes Neukoelln Medical Center, Berlin in Germany.

Highlights from the survey among 902 AF patients:
•64% of patients surveyed said it would give them ‘peace of mind, allowing them to worry less about their health’ if they knew that the effects of their blood thinning medication could be reversed in case of an emergency.
•Nearly 1 in 4 (23%) indicated they would feel ‘confident’ if they knew that there was a medication available that could stop the blood thinning effects of their anticoagulant treatment in case of an emergency.
•31% said it would allow them to live a more active lifestyle.

“It is essential that AF patients continue their prescribed anticoagulant treatment as this reduces the risk of an AF-related stroke. If they have concerns about the implications of their treatment in rare emergency situations like an accident they should openly discuss their questions with their treating physician,” said Waheed Jamal, MD, Corporate Vice President & Head of Cardiometabolic Medicine at Boehringer Ingelheim.

Survey Design
An online poll was conducted by Branding Science, an independent market research consultancy, on behalf of Boehringer Ingelheim in five countries between October and November 2017 amongst patients diagnosed with AF who have been prescribed a blood thinning (anticoagulation) therapy for stroke prevention.

The poll sought to evaluate patient attitudes towards anticoagulation and potential reversal in an emergency. It was conducted among 902 AF patients living in Belgium, Germany, Italy, Russia and the US. The respondents were 63% male and 37% female with 39% of the patients between 56 and 70 years of age being on blood thinning treatment because of AF for 6.8 years on average.
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/atrial-fibrillation-poll

View source version on businesswire.com: https://www.businesswire.com/news/home/20180628006021/en/

CONTACT:
Boehringer Ingelheim
Media Contact
Meike Bausinger
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

訊息來源:business wire
  

Top 中央社訊息平台首頁
新聞稿刊載服務請洽本社業務行銷中心人員,電話(02)2505-1180 轉 781 ~ 786 或 790 ~ 797 本平台資料均由投稿單位輸入後對外公布,資料如有錯誤、遺漏或虛偽不實,均由投稿單位負責
關閉提示
訊息提示
顯示提示